Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Growth in Short Interest

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 20,300 shares, an increase of 18.0% from the February 13th total of 17,200 shares. Approximately 0.6% of the company’s stock are sold short. Based on an average daily volume of 30,300 shares, the short-interest ratio is currently 0.7 days.

Assembly Biosciences Price Performance

ASMB opened at $10.85 on Thursday. The company has a 50-day moving average of $13.13 and a 200-day moving average of $15.21. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton bought 3,202 shares of Assembly Biosciences stock in a transaction dated Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the acquisition, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares during the period. Palumbo Wealth Management LLC acquired a new position in Assembly Biosciences in the 4th quarter valued at approximately $180,000. Marshall Wace LLP increased its stake in Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 2,098 shares during the period. FMR LLC grew its position in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares in the last quarter. Finally, Man Group plc bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $309,000. Institutional investors own 19.92% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.